Skip to main content
. 2020 Apr 14;2(1):vdaa051. doi: 10.1093/noajnl/vdaa051

Figure 2.

Figure 2.

Marizomib (MRZ) inhibits atypical teratoid/thabdoid tumor (AT/RT) cells at clinically achievable doses and in 3D culture. (A–E) Dose response curves to 5-d treatment with either MRZ or CFZ for MAF-737A (A), MAF-1298A (B), MAF-1337A (C), BT12 (D), and BT16 (E) cell lines, by CellTiter-Glo. Error bars indicate the standard error of the mean. (F–J) Cell viability after dosing with MRZ twice weekly for 14 days at 0, 10, 25, and 50 nM MRZ for MAF-737A (F), MAF-1298A (G), MAF-1337A (H), BT12 (I), and BT16 (J) cell lines. Viability is shown as absorbance per well after fixation and staining with crystal violet. (K) Neurosphere volume after 7-d growth is significantly reduced by MRZ. Neurospheres were allowed to form, treated with 100 nM MRZ, and measured after 7 days. Statistics are generated by 1-way ANOVA. (L and M) BT16 neurosphere treated with Dimethyl sulfoxide (DMSO) control (L) versus 100 nM MRZ (M). Scale bar is 400 µm.